What is the pathophysiology of Ehler Danlos Syndrome (EDS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Ehlers-Danlos Syndrome

Fundamental Molecular Defects

Ehlers-Danlos syndrome results from genetic mutations affecting collagen synthesis, structure, or post-translational modification, leading to defective connective tissue throughout the body. 1

The pathophysiology varies by subtype but centers on disrupted collagen biology:

Vascular EDS (Type IV) - Most Severe Pathophysiology

  • COL3A1 gene mutations cause production of structurally abnormal type III collagen by fibroblasts, with mutations widely distributed throughout this large, fragmented gene 1
  • The defective type III collagen leads to arterial and organ fragility, creating risk for spontaneous rupture without preceding dilatation 2, 1
  • Almost every family has its own unique mutation, and no genotype-phenotype correlations exist—the specific mutation does not predict disease severity or course 1

Classical EDS (Types I and II)

  • COL5A1 or COL5A2 gene mutations disrupt type V collagen, which regulates fibril diameter and organization 3
  • This results in the characteristic skin hyperextensibility and tissue fragility 1

Hypermobile EDS (hEDS) - Most Common Type

  • No causative genes have been identified despite accounting for 80-90% of all EDS cases 1, 3
  • Skin biopsies reveal altered collagen fibril structure that triggers fibroblast dysfunction within connective tissue, causing abnormal adhesion and cytoskeletal response 1
  • The pathophysiology likely involves multiple genetic and environmental factors rather than a single gene defect 4

Spondylodysplastic and Musculocontractural EDS

  • B4GALT7 or B3GALT6 mutations (spondylodysplastic type) impair enzymes that initiate glycosaminoglycan synthesis 5
  • CHST14 or DSE mutations (musculocontractural type) disrupt dermatan sulfate biosynthesis 5
  • These represent proteoglycan abnormalities rather than direct collagen defects 5

Pathogenetic Cascade and Clinical Manifestations

Cardiovascular Pathophysiology

  • Defective collagen in arterial walls leads to aortic root dilation in 25-33% of hypermobile and classical EDS cases 6, 1
  • In vascular EDS, arterial walls are prone to spontaneous dissection and rupture even without aneurysm formation 2
  • The median survival for vascular EDS is only 48 years due to arterial complications 3

Musculoskeletal Pathophysiology

  • Abnormal collagen in joint capsules, ligaments, and tendons causes joint hypermobility with recurrent dislocations and subluxations 6, 1
  • Defective periosteal collagen contributes to osteoporosis in 44% of cases 6
  • Altered connective tissue mechanics lead to chronic joint and limb pain 6

Dermatologic Pathophysiology

  • Disrupted dermal collagen architecture produces soft, velvety, or hyperextensible skin depending on subtype 6, 1
  • Impaired wound healing results from defective collagen deposition, causing tissue fragility and abnormal scarring 2, 7

Gastrointestinal Pathophysiology

  • Up to 98% of hEDS patients experience GI manifestations including reflux, abdominal pain, constipation, and bloating 6
  • The mechanism involves visceral hypersensitivity rather than true dysmotility in most cases 6
  • Defective connective tissue in the GI tract contributes to functional bowel disorders 6

Autonomic Pathophysiology

  • Altered connective tissue in blood vessels and autonomic nerves contributes to postural orthostatic tachycardia syndrome (POTS) 6
  • This manifests as orthostatic intolerance with heart rate increases ≥30 beats/min upon standing 6, 3

Inheritance Patterns and Genetic Heterogeneity

  • Classical and vascular EDS follow autosomal dominant inheritance, though some patients show recessively inherited presentations 1
  • Genetic heterogeneity exists—each family typically has its own specific mutation, making systematic screening impractical 1, 3
  • A total of 19 different causative genes have been identified across the 12 monogenic EDS subtypes 1, 8

Critical Pathophysiologic Distinctions

Tissue Fragility Mechanisms

  • In vascular EDS, tissue fragility occurs without skin hyperextensibility, distinguishing it from other subtypes 6
  • The absence of skin fragility is essential to distinguish hEDS from other types 6

Pregnancy-Related Pathophysiology

  • During pregnancy, women with EDS show increased bruising, hernias, varicosities, and risk of vascular rupture 2
  • Postpartum hemorrhage may be severe due to defective vascular collagen 2
  • Incisions heal slowly, requiring extended suture retention (at least 14 days) to avoid wound dehiscence 2

References

Guideline

Ehlers-Danlos Syndrome Diagnosis and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis of Ehlers-Danlos Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.

Developmental dynamics : an official publication of the American Association of Anatomists, 2021

Research

Ehlers Danlos Syndrome with Glycosaminoglycan Abnormalities.

Advances in experimental medicine and biology, 2021

Guideline

Ehlers-Danlos Syndrome Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

A review of Ehlers-Danlos syndrome.

JAAPA : official journal of the American Academy of Physician Assistants, 2020

Research

Genetic diagnosis of the Ehlers-Danlos syndromes.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.